S-1/A: Functional Brands Files S-1/A for Nasdaq Direct Listing

Functional Brands Inc. filed an S-1/A for a direct listing on the Nasdaq Capital Market, aiming to register 17.88 million shares and raise $8 million through a private placement, despite recurring losses and a going concern doubt.

Summary

• Functional Brands Inc. is pursuing a direct listing on the Nasdaq Capital Market under the symbol MEHA, registering up to 17,883,693 shares of common stock for resale by existing stockholders.
• The company has secured a private placement transaction for Series A and Series B Convertible Preferred Stock, with a stated value of $10,000,000 for Series A and $8,000,000 for Series B, totaling $8,000,000 in funding.
• Proceeds from the private placement are intended to cure an existing default of $2,227,366 related to the Kirkman acquisition, and for sales, marketing, and general working capital.
• The company operates in two main segments: nutraceuticals (Kirkman brand) and hemp-derived products (HempTown Naturals brand).
• The Kirkman brand, established in 1949, offers over 150 products and recently launched P2i by Kirkman, a certified prenatal vitamin aligning with FIGO's low-toxicity standards.
• HempTown Naturals products comply with the US 2018 Farm Bill and 2014 Agricultural Act, with sales restricted to states permitting such activity.
• The company is negotiating the termination of an exclusive license agreement with Trailer Park Boys for hemp-derived Delta 9 products, effective December 31, 2025, with up to $150,000 in remaining accrued royalties due by March 31, 2026.
• Functional Brands has suffered recurring losses from operations, negative cash flows, and a significant accumulated deficit of $8,013,768 as of June 30, 2025.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• Net loss for the six months ended June 30, 2025, was $352,838, a significant decline from a net income of $6,475 for the same period in 2024.
• Net loss for the year ended December 31, 2024, was $559,356, an improvement from $1,241,094 in 2023.
• Revenue decreased by 2% to $3,422,789 for the six months ended June 30, 2025, and by 4% to $6,566,455 for the year ended December 31, 2024, primarily due to lower demand from contract manufacturing customers.
• Cash on hand as of June 30, 2025, was $257,683, with anticipated cash needs of approximately $3,600,000 for working capital and capital expenditures over the next twelve months.
• The company will qualify as an emerging growth company and a smaller reporting company, allowing for reduced public company reporting requirements.
• The board of directors will expand to five members, including three independent directors (Girard Smith, Lourdes Felix, Steven Rossi), upon the registration statement's effectiveness.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by recurring losses, negative cash flow, a substantial accumulated deficit, and an explicit 'going concern' doubt from its auditors. While there are growth strategies and product innovations, the immediate financial instability, including a significant acquisition payment default with foreclosure risk, and the inherent volatility of a direct listing without traditional underwriting support, present an extremely high-risk profile. The recent deterioration in net income/loss for the most recent six-month period further exacerbates these concerns.

Positives

• Successfully launched P2i by Kirkman prenatal vitamin, which is certified as the only one aligning with FIGO's low-toxicity standards, targeting a growing market of 3.6 million pregnancies in the U.S. alone.
• The Kirkman brand boasts over 70 years of operation with a loyal consumer base and maintains high purity and quality standards, operating in 95% of major supplement subsegments.
• Rigorous product testing standards, including analysis for 24 heavy metals and 120 toxic chemicals, exceed FDA requirements for dietary supplements.
• Cost of goods sold decreased by 3% for the six months ended June 30, 2025, and by 19% for the year ended December 31, 2024, indicating effective cost control measures.
• Operating loss decreased by 79% for the year ended December 31, 2024, reflecting efforts to stabilize the company's financial performance.
• Net loss decreased by 55% for the year ended December 31, 2024, showing an improvement in profitability compared to the previous year.
• Strategic growth plan includes strengthening the Kirkman brand, launching multiple new brands, modernizing manufacturing capabilities, and investing in sales/marketing and business development.
• Secured $8,000,000 in private placement funding, which is crucial for addressing immediate financial obligations and supporting growth initiatives.
• The company will cease to be a controlled company, which can enhance corporate governance and investor confidence.

Negatives

• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• Suffered recurring losses from operations and has a significant accumulated deficit of $8,013,768 as of June 30, 2025.
• Experienced negative cash flows from operations, indicating ongoing liquidity challenges.
• Reported a net loss of $352,838 for the six months ended June 30, 2025, a significant deterioration from a net income of $6,475 in the comparable prior year period.
• Revenue decreased by 2% for the six months ended June 30, 2025, and by 4% for the year ended December 31, 2024, primarily due to lower demand from contract manufacturing customers.
• Selling and marketing costs increased by 15% for the six months ended June 30, 2025, and general and administrative expenses increased by 17% for the same period, impacting profitability.
• Other expenses increased by 39% for the six months ended June 30, 2025, mainly due to interest on new loans.
• A significant outstanding balance of $2,227,366 for the Kirkman acquisition is due by September 30, 2025, with a confession of judgment allowing for foreclosure if defaulted.
• High reliance on two major customers (iHerb and OceanSide Health) which accounted for 55% of sales for H1 2025 and 54% for FY 2024, posing a concentration risk.
• Negotiating the termination of the Trailer Park Boys license agreement, which contributed approximately 0.6% of total company revenue.
• The direct listing process is novel and may lead to higher price volatility and uncertain trading volume compared to traditional underwritten IPOs.
• There is no assurance that the Nasdaq listing application will be approved, which is a condition to the offering and private placement.
• The company will not receive any proceeds from the resale of shares by Registered Stockholders in this offering.
• No current plans to pay cash dividends on common stock in the foreseeable future.

Risks

• Independent registered public accounting firm has expressed substantial doubt about the ability to continue as a going concern.
• May be unable to effectively manage future growth, leading to capacity constraints and pressure on internal systems.
• Will need additional financing in the future, which may not be available when needed or may be costly and dilutive to existing shareholders.
• If unable to continue as a going concern, securities will have little or no value.
• Has a limited operating history, particularly in hemp operations, making it difficult to evaluate proposed business and prospects.
• May incur significant debt to finance operations, with no assurance of sufficient funds to repay or avoid default.
• Existing events of default under the Asset Purchase Agreement for the Kirkman acquisition could have a material adverse effect on financial condition, results of operations, and prospects, including potential foreclosure.
• Competes in an industry that is brand-conscious, so brand name recognition and acceptance of products are critical to success, and any inability to maintain a positive brand image could have a material adverse effect.
• Competition from traditional and large, well-financed product manufacturers or distributors may adversely affect distribution relationships and hinder market development.
• Operates in an industry characterized by rapid changes in consumer preferences and public perception, requiring continuous product development to maintain long-term success.
• May be unable to respond effectively to technological changes in the industry, which could reduce demand for products.
• May experience reduced demand for some products due to health concerns and legislative initiatives against smokables products.
• Legislative or regulatory changes that affect products, including new taxes, could reduce demand or increase costs.
• Some products are subject to developing and unpredictable federal, state, and local regulations concerning hemp, CBD, CBG, and other non-tobacco consumable products, which could have a material adverse effect.
• Ability to develop, commercialize, and distribute hemp-derived products and comply with evolving laws and regulations may affect operational results, including risks of products being intercepted as marijuana.
• International expansion efforts would likely significantly increase operational expenses and associated risks.
• Reliance on distributors, retailers, and brokers could affect the ability to efficiently and profitably distribute and market products, and loss of these accounts would harm the business.
• Has two customers (iHerb and OceanSide Health) that account for a substantial portion of revenues, and loss of these customers would significantly harm the business.
• Wholesale price volatility for hemp and other product ingredients may adversely affect operations and profitability.
• May sustain losses that cannot be recovered through insurance or other preventative measures, as current liability coverage is limited.
• May be subject to product liability claims and other claims from customers and partners, which could be costly and damage reputation.
• Product recalls or other product quality issues could tarnish image and affect profitability.
• Difficulty in predicting the timing and amount of sales, leading to uncertain sales forecasts.
• Inadequate management of inventory levels could adversely affect operating results.
• Increases in costs or shortages of raw materials could harm business and financial results.
• Increases in costs of energy and increased regulations may have an adverse impact on gross margin.
• Disruption within the supply chain, contract manufacturing, or distribution channels could have an adverse effect on business.
• Inability to attract and retain key personnel, or loss of executive officers (CEO and CFO), would adversely affect efficiency and operations.
• Failure to protect trademarks and trade secrets may hinder successful product marketing and effective competition.
• Disruptions to information technology systems due to cyber-attacks or failure to upgrade IT systems may materially impair operations.
• Business is subject to many regulations, and noncompliance is costly.
• Significant additional labeling or warning requirements may inhibit sales of affected products.
• Industry may become subject to expanded regulation and increased enforcement by the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC).
• Results of operations may fluctuate from quarter to quarter due to various factors, including seasonality.
• Global economic, political, social, and other conditions, including geopolitical instability and potential tariffs, may continue to adversely impact business.
• May not be able to satisfy listing requirements of NASDAQ or obtain or maintain a listing of common stock on NASDAQ.
• The direct listing process differs significantly from an initial public offering, potentially leading to greater price and volume volatility.
• Retention of Joseph Gunnar & Co. LLC as financial advisor may create potential conflicts of interest.
• Common stock currently has no public market, and an active trading market may not develop or be sustained.
• A direct listing complicates the ability for a plaintiff to make a claim under Section 11 of the Securities Act due to traceability requirements.
• Future sales of common stock by Registered Stockholders and other existing stockholders could cause the share price to decline.
• May be diluted by future issuances of preferred stock or additional common stock in connection with incentive plans, acquisitions, or otherwise.
• No current plans to pay cash dividends on common stock, meaning shareholders may not receive a return unless they sell their shares.
• If securities industry analysts do not publish research reports or publish unfavorable reports, the market price and trading volume could be negatively affected.
• Future issuances of debt securities (senior to common stock) or preferred stock (senior for dividends/liquidating distributions) may adversely affect the return from an investment in common stock.
• Authorized to issue blank check preferred stock without stockholder approval, which could adversely impact the rights of common stockholders.
• If shares of common stock become subject to penny stock rules, it would become more difficult to trade shares.
• Subject to ongoing public reporting requirements that are less rigorous as an emerging growth company and smaller reporting company, potentially making common stock less attractive to some investors.

Future Outlook

The company aims to become a leader in the nutraceutical space by upholding high quality standards for products, expanding its portfolio to include mushroom-based supplements, prenatal vitamins, and athlete-focused products. It plans to strengthen the Kirkman brand, launch new brands like P2i by Kirkman globally, modernize manufacturing facilities, and significantly increase investment in sales, marketing, and business development. The company also intends to identify synergistic partnerships or acquisitions. It anticipates continued operating losses and will require additional financing beyond current cash and cash flow from operations for the next six months, planning to seek further equity and/or debt financing. The common stock is expected to begin trading on Nasdaq on or about September __, 2025, under the symbol MEHA.

Management Comments

• "We aim to be a leader in the nutraceutical space by manufacturing products held to the highest standard of quality in terms of toxins, metals, and other impurities."
• "Our goal is to build a well-rounded portfolio of products including mushroom-based supplements targeted for everyday use, prenatal, athletes and beyond."
• "We believe it is imperative that we meet these sales objectives in order to lessen our reliance on external financing in the future."
• "We intend to continually monitor and adjust our operating plan as necessary to respond to developments in our business, our markets and the broader economy."
• "We believe that our current cash and cash flow from operations will only be sufficient to meet anticipated cash needs for the next six months for working capital and capital expenditures."

Industry Context

The company operates within the growing global nutraceutical and dietary supplement markets, valued at approximately $405.15 billion and $53.6 billion respectively in 2023, with projected CAGRs of 6.3% and 5.7% through 2030. The global prenatal vitamin market, valued at $542.8 million in 2023, is expected to grow at an 8.5% CAGR. The global CBD consumer health market, valued at $19.5 billion in 2023, is anticipated to grow at an 18.1% CAGR. The FDA is currently exploring new regulatory pathways for CBD products, not regulating them as dietary supplements, which creates both uncertainty and opportunity for companies like Functional Brands. The company's focus on high-purity, certified products, such as the P2i prenatal vitamin, positions it to capitalize on increasing consumer health awareness and demand for quality supplements.

Comparison to Industry Standards

• The Kirkman brand's 75+ year history and rigorous material testing, including for approximately 90 metals and toxins in raw materials and 24 heavy metals and 120 toxic chemicals in finished products, are presented as exceeding FDA requirements for dietary supplements, which the FDA does not mandate.
• The P2i by Kirkman prenatal vitamin is highlighted as the 'only certified prenatal vitamin in the market that aligns to the FIGO position statement' for low-toxicity standards, differentiating it in the prenatal supplement market.
• In the multi-vitamin segment, market leaders include private label store brands, Nature Made, Centrum, One-A-Day, and Nature's Bounty, with Kirkman operating in 95% of major subsegments.
• Leaders in the broader supplement category include Nature's Bounty, Nature Made, Emergen-C, Baush+Lomb, and Airbourne, indicating a competitive landscape.
• The company's ability to produce capsules, tablets, liquids, and powders allows it to compete effectively with core competitors across various product delivery methods.
• Competitors in the special needs category include New Beginnings, Claire Labs, Houston Enzymes, and Lifetrients, focusing on dietary sensitivities.
• In the hemp industry, competitors include Charlottes Web, cbdMD, Social CBD, Joy Organics, and MedTerra, with limited market share data due to online sales dominance.

Management Changes

Corporate Governance

Legal Proceedings

• True Health Medical Center, S.C. (True Health) amended an existing complaint against Kirkman Group, Inc., James Hall, David Humphries, HTO Nevada, Inc., and HTO Holdings, Inc. (HTO Parties) in the Circuit Court for the Eighteenth Judicial Circuit, DuPage County, Illinois.
• True Health claims Kirkman underpaid royalties prior to selling its assets to the HTO Parties, and the HTO Parties have never paid royalties to True Health.
• True Health contends that as the purchaser of certain Kirkman assets, the HTO Parties should be bound by the terms of the royalty agreement.
• There is no certain amount of damages claimed against the HTO Parties at this time, and the outcome of the proceeding is not possible to predict.
• Fact and expert discovery have largely been completed, but Kirkman Group recently filed a motion for leave to amend its counterclaims against True Health, which could lead to additional discovery and further delay the trial date.
• No trial date has been scheduled at this time.

Related Party Transactions

• On March 7, 2025, a loan agreement was executed with Eric Gripentrog, the Chief Executive Officer, for $225,000 with an annual interest rate of 18%, maturing on March 7, 2029.
• On March 11, 2024, a loan agreement was executed with Eric Gripentrog, the Chief Executive Officer, for $130,000 with an annual interest rate of 20%, maturing on March 10, 2031.
• In December 2023, the company entered into a short-term non-interest-bearing debt facility with an officer and director of the parent company, Hemptown Organics Corp., for $247,634. This loan was reclassed from related party to loans payable in January 2025 after the officer and director resigned.
• Hemptown Organics Corp. (HOC), the previous majority owner, distributed all its shares in Functional Brands to its shareholders and debtholders, resulting in Functional Brands ceasing to be a controlled company.
• The licensing agreement dated December 10, 2020, with Hemptown Organics Corp. for the Hemptown USA and Hemptown Naturals brands will transfer full ownership to Functional Brands upon the effective date of the registration statement and listing on the exchange.

Stakeholder Impact

• Shareholders face potential dilution from future issuances of preferred stock or additional common stock in connection with incentive plans, acquisitions, or otherwise. The direct listing process may also lead to significant price volatility and uncertain trading volume, and there are no current plans to pay cash dividends.
• Employees' success depends on the company's ability to attract and retain highly qualified personnel. The loss of key executive officers (CEO and CFO) could materially impair future operations.
• Customers of the Kirkman brand benefit from a long-standing reputation for quality and the introduction of innovative, certified products like P2i prenatal vitamins. However, the company's reliance on two major customers (iHerb and OceanSide Health) for a significant portion of revenue poses a risk if these relationships are disrupted.
• Suppliers of raw materials, particularly for hemp-based products, are critical to operations. Disruptions in the supply chain or significant price increases could negatively impact the business.
• Creditors, especially the seller in the Kirkman acquisition, face risks due to the outstanding balance of $2,227,366 and the confession of judgment, which allows for foreclosure in case of default. New loan agreements also introduce additional interest expenses.

Next Steps

• Complete the Direct Listing on the Nasdaq Capital Market under the symbol MEHA.
• Secure approval for the Nasdaq listing application.
• Close on the private placement of preferred stock, which is conditioned upon the Direct Listing.
• Cure the existing default of $2,227,366 for the Kirkman acquisition by the extended due date of September 30, 2025, utilizing proceeds from the private placement.
• Strengthen the existing 70-year-old Kirkman brand by curating its product mix to cater to the specific needs of the autism community.
• Launch multiple new brands, including the P2i by Kirkman prenatal vitamin, with an expectation to expand globally.
• Modernize manufacturing capabilities by reorganizing space and introducing new and efficient machinery and equipment.
• Invest heavily into sales and marketing activities as well as business development to increase sales and distribution.
• Identify key companies with synergistic strengths for partnerships or acquisitions.
• Finalize the negotiation for the termination of the exclusive license agreement with Trailer Park Boys, effective December 31, 2025, and pay remaining accrued royalties by March 31, 2026.
• Seek additional equity and/or debt financing to support anticipated working capital needs for the next twelve months.
• The board of directors will expand to five members, with three independent directors, upon the effective date of the registration statement.

Key Dates

Recommendation

The company's financial position is highly precarious, marked by recurring losses, negative cash flows, and an accumulated deficit of over $8 million. The independent auditor's 'going concern' doubt is a critical red flag. While a private placement of $8 million is anticipated, a significant portion is earmarked to cure an existing default on a $2.2 million acquisition payment, which carries a foreclosure risk. The direct listing itself is a novel and inherently volatile process, lacking traditional underwriting support, which could lead to significant and rapid share price declines. Revenue is decreasing, and while cost controls are noted, the recent six-month period shows a sharp increase in net loss. Given the severe financial instability, high operational risks, and the speculative nature of the direct listing, the investment carries an exceptionally high risk of capital loss.

Keywords

Nutraceuticals, Supplements, Hemp, CBD, CBG, Direct Listing, Nasdaq, SEC Filing, Financial Performance, Risk Factors, Corporate Governance, P2i, Kirkman, Functional Brands Inc., S-1/A, Private Placement, Going Concern, Health Supplements, Prenatal Vitamins, Cannabinoids